, Tracking Stock Market Picks
Enter Symbol:
Rating: JUNO
up 41.00 %

Juno Therapeutics Inc. (NASDAQ: JUNO) downgraded to Hold by Standpoint Research

Thursday,  Oct 29, 2015  10:25 AM ET by Lynn Gilbert

Standpoint Research downgraded Juno Therapeutics Inc. (NASDAQ: JUNO) to Hold. Previously, Standpoint Research rated Juno Therapeutics Inc. (NASDAQ: JUNO) to Buy with price target $47
on 08/24/2015, when the stock price was valued at $37.29. Since then, Juno Therapeutics Inc.'s stock price has gained 41% as of 10/29/2015's recent price of $52.67.
If you had followed Standpoint Research's previous recommendation on JUNO, you would have gained 41% of your investment in 66 days.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy